Peran Infeksi Bakteri Patogen pada Jalur Inflamasi dalam Patogenesis Kolitis Ulseratif: Tinjauan Pustaka

Lismayana Hansur; Paisal

doi:10.56951/8yr1a459

Peran Infeksi Bakteri Patogen pada Jalur Inflamasi dalam Patogenesis Kolitis Ulseratif: Tinjauan Pustaka

Penulis

Lismayana Hansur Departemen mikrobiologi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Muhammadiyah Makassar, Makassar, Sulawesi Selatan, Indonesia
Paisal Pusat Penelitian Praklinis dan Klinik, Badan Riset dan Inovasi Nasional, Jakarta, Indonesia

DOI:

https://doi.org/10.56951/8yr1a459

Kata Kunci:

infeksi bakteri, disbiosis, mikrobiota usus, penyakit radang usus, bakteri patogen, kolitis ulseratif

Abstrak

Kolitis ulseratif adalah penyakit radang usus kronis yang ditandai oleh inflamasi mukosa usus besar. Disbiosis mikrobiota usus dan infeksi bakteri patogen berperan penting dalam patogenesis dan progresi penyakit. Metode: Studi ini merupakan
tinjauan pustaka yang dilakukan melalui pencarian literatur secara sistematis menggunakan database PubMed, Scopus, dan Google Scholar, mencakup publikasi dari tahun 2014 hingga 2024. Pencarian difokuskan pada keterlibatan strain bakteri patogen dan mekanisme imun-inflamasi. Hasil: Beberapa bakteri seperti Bacteroides fragilis, Escherichia coli patogenik, dan spesies Klebsiella diketahui mengganggu integritas mukosa usus dan memicu inflamasi melalui aktivasi inflammasome serta jalur sitokin interleukin (IL)-17/IL-23. Disbiosis juga menyebabkan penurunan produksi metabolit
protektif seperti asam lemak rantai pendek (short-chain fatty acid/SCFA). Kesimpulan: Pemahaman mendalam mengenai interaksi antara infeksi bakteri patogen, disbiosis mikrobiota usus, dan respons imun inang menjadi kunci dalam
pengembangan strategi diagnosis untuk meredakan kolitis ulseratif.

Unduhan

Baca Selengkapnya

Referensi

1. Rasmussen B, Haastrup P, Wehberg S, Kjeldsen J, Waldorff FB. Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. Scand J Gastroenterol. 2020;55:656–63. doi:10.1080/00365521.2020.1768282.

2. Nag A, Romero B. Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn’s disease in adults with moderate-to-severe disease. Health Qual Life Outcomes. 2022;20:75. doi:10.1186/s12955-022-01975-1.

3. Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16:26–42. doi:10.5217/ir.2018.16.1.26.

4. Aniwan S, Santiago P, Loftus EVJ, Park SH. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. United European Gastroenterol J. 2022;10:1063–76. doi:10.1002/ueg2.12350.

5. Gorospe J, Windsor J, Hracs L, Coward S, Buie M, Quan J, et al. Trends in inflammatory bowel disease incidence and prevalence across epidemiologic stages: a global systematic review with meta-analysis. Gastroenterology. 2024;166(3):S56–7. doi:10.1053/j.gastro.2023.11.136.

6. Orel R, Kamhi Trop T. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol. 2014;20:11505–24. doi:10.3748/wjg.v20.i33.11505.

7. Calvez V, Puca P, Di Vincenzo F, Del Gaudio A, Bartocci B, Murgiano M, et al. Novel insights into the pathogenesis of inflammatory bowel diseases. Biomedicines. 2025;13(2):305. doi:10.3390/biomedicines13020305.

8. Vidal-Gallardo A, Benítez JEM, Rios LF, Meza LFO, Pérez RAM, Romero EM, et al. The role of gut microbiome in the pathogenesis and the treatment of inflammatory bowel diseases. Cureus. 2024;16:e54569. doi:10.7759/cureus.54569.

9. Świrkosz G, Szczygieł A, Logoń K, Wrześniewska M, Gomułka K. The role of the microbiome in the pathogenesis and treatment of ulcerative colitis-a literature review. Biomedicines. 2023;11(12):3144. doi:10.3390/biomedicines11123144.

10. Dai ZF, Ma XY, Yang RL, Wang HC, Xu DD, Yang JN, et al. Intestinal flora alterations in patients with ulcerative colitis and their association with inflammation. Exp Ther Med. 2021;22:1322. doi:10.3892/etm.2021.10757.

11. Zou J, Liu C, Jiang S, Qian D, Duan J. Cross talk between gut microbiota and intestinal mucosal immunity in the development of ulcerative colitis. Infect Immun. 2021;89:e0001421. doi:10.1128/IAI.00014-21.

12. Liu Q, Lu W, Tian F, Zhao J, Zhang H, Hong K, et al. Akkermansia muciniphila exerts strain-specific effects on DSS-induced ulcerative colitis in mice. Front. Cell. Infect. Microbiol. 2021;11:698914. doi:10.3389/fcimb.2021.698914

13. Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 immune axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges. Front Immunol. 2021:12:611256. doi:10.3389/fimmu.2021.611256.

14. Leccese G, Bibi A, Mazza S, Facciotti F, Caprioli F, Landini P, et al. Probiotic Lactobacillus and Bifidobacterium strains counteract adherent-invasive Escherichia coli (AIEC) virulence and hamper IL-23/Th17 axis in ulcerative colitis, but not in Crohn’s disease. Cells. 2020;9(8):1824. doi:10.3390/cells9081824.

15. Xue S, Xue Y, Dou D, Wu H, Zhang P, Gao Y, et al. Kui jie tong ameliorates ulcerative colitis by regulating gut microbiota and NLRP3/caspase-1 classical pyroptosis signaling pathway. Dis Markers. 2022:2022:2782112. doi:10.1155/2022/2782112.

16. Zhang L, Liu F, Xue J, Lee SA, Liu L, Riordan SM. Bacterial species associated with human inflammatory bowel disease and their pathogenic mechanisms. Front. Microbiol. 2022;13:801892. doi:10.3389/fmicb.2022.801892.

17. Singh V, Johnson K, Yin J, Lee S, Lin R, Yu H, et al. Chronic inflammation in ulcerative colitis causes longterm changes in goblet cell function. Cell Mol Gastroenterol Hepatol. 2022;13(1):219–2. doi:10.1016/j. jcmgh.2021.08.010.

18. Yao D, Dai W, Dong M, Dai C, Wu S. MUC2 and related bacterial factors: therapeutic targets for ulcerative colitis. EBioMedicine. 2021:74:103751. doi:10.1016/j.ebiom.2021.103751.

19. Huang H, Yang C, Li S, Zhan H, Tan J, Chen C, et al. Lizhong decoction alleviates experimental ulcerative colitis via regulating gut microbiota-SCFAs-Th17/Treg axis. J Ethnopharmacol. 2025;349:119958. doi:10.1016/j.jep.2025.119958.

20. Zhang Y, Han J, Gao J, Ge Q, Zhang H, Shi J, et al. Polysaccharide from Pyrus pashia Buch ameliorates DSS-induced colitis in mice via MAPKP38/NF-κB P65 and SCFAs/ERK/MSK signaling pathways. Phytomedicine. 2025;140:156561. doi:10.1016/j.phymed.2025.156561.

21. Kałużna A, Olczyk P, Komosińska-Vassev K. The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis. J Clin Med. 2022;11(2):400. doi:10.3390/jcm11020400.

22. Drury B, Hardisty G, Gray RD, Ho G. Neutrophil extracellular traps in inflammatory bowel disease: pathogenic mechanisms and clinical translation. Cell Mol Gastroenterol Hepatol. 2021;12(1):321–33. doi:10.1016/j.jcmgh.2021.03.002.

23. Zhang J, Wang X, Xu L, Zhang Z, Wang F, Tang X. Investigation of potential genetic biomarkers and molecular mechanism of ulcerative colitis utilizing bioinformatics analysis. Biomed Res Int. 2020;2020:4921387. doi:10.1155/2020/4921387.

24. Chen Y, Chen Y, Cao P, Su W, Zhan N, Dang W. Fusobacterium nucleatum facilitates ulcerative colitis through activating IL‐17F signaling to NF‐κB via the upregulation of CARD3 expression. J Pathol. 2020;250(2):170–82. doi:10.1002/path.5358.

25. Liang L, Yang C, Liu L, Mai G, Li H, Wu L, et al. Commensal bacteria-derived extracellular vesicles suppress ulcerative colitis through regulating the macrophages polarization and remodeling the gut microbiota. Microb Cell Fact. 2022;21(1):88. doi:10.1186/s12934-022-01812-6.

26. Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev. 2019;32:10.1128/cmr.00060-18. doi:10.1128/cmr.00060-18.

27. Wu X, Chen G, Yang L, Lv Z, Wu Y, Liang C, et al. Comprehensive antibiotic resistome comparison of Escherichia coli from irritable bowel syndrome and ulcerative colitis. Curr Res Microb Sci. 2025;8:100398. doi:10.1016/j.crmicr.2025.100398.

28. Yang H, Mirsepasi-Lauridsen HC, Struve C, Allaire JM, Sivignon A, Vogl W, et al. Ulcerative colitisassociated E. coli pathobionts potentiate colitis in susceptible hosts. Gut Microbes. 2020;12:1847976. doi:10.1080/19490976.2020.1847976.

29. Khorsand B, Aghdaei HA, Nazemalhosseini-Mojarad E, Nadalian B, Nadalian B, Houri H. Overrepresentation of Enterobacteriaceae and Escherichia coli is the major gut microbiome signature in Crohn’s disease and ulcerative colitis; a comprehensive metagenomic analysis of IBDMDB datasets. Front Cell Infect Microbiol. 2022:12:1015890. doi:10.3389/fcimb.2022.1015890.

30. Mills RH, Dulai PS, Vázquez-Baeza Y, Sauceda C, Daniel N, Gerner RR, et al. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat Microbiol. 2022;7:262–76. doi:10.1038/s41564-021-01050-3.

31. Su W, Chen Y, Cao P, Chen Y, Guo Y, Wang S, et al. Fusobacterium nucleatum promotes the development of ulcerative colitis by inducing the autophagic cell death of intestinal epithelial. Front Cell Infect Microbiol. 2020:10:594806. doi:10.3389/fcimb.2020.594806.

32. Raffelsberger N, Hetland MAK, Svendsen K, Småbrekke L, Löhr IH, Andreassen LLE, et al. Gut Microbes. 2021;13(1):1939599. doi:10.1080/19490976.2021.1939599.

33. Wan J, Zhang Y, He W, Tian Z, Lin J, Liu Z, et al. Gut microbiota and metabolite changes in patients with ulcerative colitis and Clostridioides difficile infection. Front Microbiol. 2022;13:802823. doi: 10.3389/fmicb.2022.802823.

34. Pilarczyk-Zurek M, Strus M, Adamski P, Heczko PB. The dual role of Escherichia coli in the course of ulcerative colitis. BMC Gastroenterol. 2016;16:128. doi:10.1186/s12876-016-0540-2.

35. López-Siles M, Camprubí-Font C, Del Pulgar EMG, Mir MS, Busquets D, Sanz Y, et al. Prevalence, abundance, and virulence of adherent-invasive Escherichia coli in ulcerative colitis, colorectal cancer, and coeliac disease. Front Immunol. 2022;13:748839. doi:10.3389/fimmu.2022.748839.

36. de Campos Silva EF, Baima JP, de Barros JR, Tanni SE, Schreck T, Saad-Hossne R, et al. Risk factors for ulcerative colitis-associated colorectal cancer: a retrospective cohort study. Medicine (Baltimore). 2020;99(32):e21686. doi:10.1097/MD.0000000000021686.

37. Nagao-Kitamoto H, Leslie JL, Kitamoto S, Jin C, Thomsson KA, Gillilland MG 3rd, et al. Interleukin- 22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota. Nat Med. 2020;26(4):608–17. doi:10.1038/s41591-020-0764-0.

38. Singh AK, Shukla S, Acharya R, Birda CL, Sah PK, Singh S, et al. Impact of Clostridioides difficile infection on the outcome of severe flare of ulcerative colitis. J Clin Gastroenterol. 2025. doi:10.1097/MCG.0000000000002196.

39. Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res. 2020;19(3):265–74. doi:10.5217/ir.2020.00045.

40. Park J, Kim S, Im JP, Lee HJ, Kim JS, Park H, et al. Clinical outcome of inflammatory bowel disease with Clostridioides difficile polymerase chain reaction toxin-positive/enzyme immunoassay toxin-negative: a retrospective cohort study. Dig Dis Sci. 2025;70(8):2794–803. doi:10.1007/s10620-025-09045-4.

41. Murgiano M, Bartocci B, Puca P, Vincenzo F di, Gaudio A Del, Papa A, et al. Gut microbiota modulation in IBD: from the old paradigm to revolutionary tools. International Journal of Molecular Sciences. 2025;26(7):3059. doi:10.3390/ijms26073059.

42. Huo L, Chen Q, Jia S, Zhang Y, Wang L, Li X, et al. Gut microbiome promotes succinate-induced ulcerative colitis by enhancing glycolysis through SUCNR1/NF-κB signaling pathway. Am J Physiol Cell Physiol. 2025;329(2):C440–54. doi:10.1152/ajpcell.00411.2025.

43. Zang R, Liu Z, Wu H, Chen W, Zhou R, Yu F, et al. Candida utilis ameliorates dextran sulfate sodiuminduced colitis in mice via NF-κB/MAPK suppression and gut microbiota modulation. Int J Mol Sci. 2025;26(5):1993. doi:10.3390/ijms26051993.

44. Cai XX, Huang YH, Lin YC, Huang HY, Chen YG, Zhang DP, et al. A comprehensive review of small molecules, targets, and pathways in ulcerative colitis treatment. Eur J Med Chem. 2025;291:117645. doi:10.1016/j.ejmech.2025.117645.

45. Xiang Z, Li X, Wang X, Deng B, He H, Xu M, et al. Fusobacterium nucleatum exacerbates colitis via STAT3 activation induced by acetyl-CoA accumulation. Gut Microbes. 2025;17(1):2489070. doi:10.1080/19490976.2025.2489070.

46. Yan T, Su T, Zhu M, Qing Q, Huang B, Liu J, et al. Oxidative stress gene expression in ulcerative colitis: implications for colon cancer biomarker discovery. Sci Rep. 2025;15(1):22641. doi:10.1038/s41598-025- 05108-8.

47. Németh ZH, Bogdanovski DA, Barratt-Stopper P, Paglinco SR, Antonioli L, Rolandelli RH. Crohn’s disease and ulcerative colitis show unique cytokine profiles. Cureus. 2017;9(4):e1177. doi:10.7759/cureus.1177.

48. Wang XH, Liu JD, Qu Y, Dong JZ, Wang JB, Xue YN, et al. Electroacupuncture improves colonic mucosal barrier damage by regulating NLRP3/Caspase-1/GSDMD signaling pathway and inhibitingpyroptosis in ulcerative colitis mice. Zhen Ci Yan Jiu. 2025;50(3):277–86. Chinese. doi:10.13702/j.1000-0607.20240402.

49. Zhou Z, Wang L, Liao R, Chen Q, Liu C, Song J, et al. The effect of GB1 on DSS-induced colitis in WT and Nlrp3-/- mice. Int J Mol Sci. 2025;26(9):4016. doi:10.3390/ijms26094016.